Abstract
A 16-year-old boy with sickle cell anemia undergoes routine screening with transcranial Doppler ultrasonography to assess the risk of stroke. This examination shows an abnormally elevated blood-flow velocity in the middle cerebral artery. The hemoglobin level is 7.2 g per deciliter, the reticulocyte count is 12.5%, and the fetal hemoglobin level is 8.0%. Long-term treatment with red-cell transfusion is initiated to prevent stroke. A hematologist recommends prophylactic iron-chelating therapy.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Adolescent
-
Anemia, Sickle Cell / therapy
-
Benzoates / therapeutic use
-
Chelation Therapy*
-
Deferasirox
-
Deferoxamine / therapeutic use
-
Erythrocyte Transfusion / adverse effects*
-
Humans
-
Iron
-
Iron Chelating Agents / administration & dosage
-
Iron Chelating Agents / adverse effects
-
Iron Chelating Agents / therapeutic use*
-
Iron Overload / drug therapy*
-
Iron Overload / etiology
-
Male
-
Practice Guidelines as Topic
-
Triazoles / therapeutic use
Substances
-
Benzoates
-
Iron Chelating Agents
-
Triazoles
-
Iron
-
Deferoxamine
-
Deferasirox